HIMSS & AMDIS Partner to Drive Digital Health Transformation
The two organizations will provide multi-modal learning experiences, opportunities to work with peers, and more.
The Healthcare Information and Management Systems Society (HIMSS) and the Association of Medical Directors of Information Systems (AMDIS) are entering into an exclusive partnership that combines both organizations global networks of health professionals. This will improve educational resources available members of both organizations that will help them adapt to digital transformation.1
The agreement builds upon the companies’ decades long relationship, combining HIMSS’ ecosystem of 125,000 individuals, 430+ provider organizations, 500+ nonprofit partners, and 550+ health services organizations with the thought and opinion leaders that make up AMDIS’ membership.1
Beyond a multi-modal educational offering, the expanded collaboration offers members additional benefits, such as opportunities for collaborative work on public policy and networking opportunities. The organizations have agreed to continue to support the HIMSS-AMDIS Physician Executive Award, as well as explore other ideas to further strengthen both of their communities.
"Through our partnership with AMDIS, we are creating a trusted network that enables physicians and health system executives to collaborate and share insights that will transform the future of the global health ecosystem, ultimately improving care delivery and patient outcomes," said Hal Wolf, president & CEO of HIMSS, in the press release. "Digital health transformation is rapidly accelerating, and this partnership will provide the tools and resources clinical leaders need to lead and support advanced infrastructures and stay at the forefront of health innovation."
The collaboration also includes to develop and cross-promote healthcare conferences with a focus on programs for clinician executives. Both organizations have existing conferences, such as the HIMSS Global Health Conference & Exhibition and the AMDIS Physician-Computer Connection Symposium.1
"We are excited to enter into this new phase of collaboration with HIMSS," said Richard L. Rydell, CEO of AMDIS, in the release. "By combining our expertise in clinical informatics with HIMSS's global influence in health technology, we can offer unprecedented educational opportunities and tools for physician leaders, ensuring they are equipped to globally advance patient care and outcomes through education, networking, and content development."
The partnership will initially focus on North America with plans to expand internationally.1
HIMSS launched veteran focused initiative in mid-November 2024. Veterans Community helps veterans of any brand on the US military develop their skills and transition them into healthcare IT positions.2 Veterans who are not currently HIMSS members will receive a free year-long membership, as well as be enrolled in their local HIMSS Chapter. With this support, HIMSS aims to make the transition to civilian life easier on military members and their partners, giving them a pipeline to earning a good living, providing health benefits for their families, and finding career growth post service.
"Our decision to launch a dedicated HIMSS community for veterans reflects a larger conversation happening across the health ecosystem about improved access to care and workforce development," said Tom Leary, HIMSS senior vice president & head of government relations. "It is vital that veterans have better access to resources and opportunities that help them embrace digital health transformation to better manage their care and start careers in the health industry."
Sources
HIMSS and AMDIS Announce Exclusive Partnership to Support Clinical Executives and Drive Digital Health Transformation. HIMSS-HEALTHCARE INFORMATION AND MANAGEMENT SYSTEMS SOCIETY. January 30, 2025. https://www.prnewswire.com/news-releases/himss-and-amdis-announce-exclusive-partnership-to-support-clinical-executives-and-drive-digital-health-transformation-302364264.html
HIMSS to Launch Veterans Community to Support Veteran Workforce Development. HIMSS-HEALTHCARE INFORMATION AND MANAGEMENT SYSTEMS SOCIETY. November 11, 2024. Accessed January 30, 2025. https://www.prnewswire.com/news-releases/himss-to-launch-veterans-community-to-support-veteran-workforce-development-302300400.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
